Birgit Geoerger
Gustave Roussy, Cancer Campus, Grand Paris
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Birgit Geoerger as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-11 16:27 UTC. Open this list on ClinicalTrials.gov
- N/ANCT05691608 · MoleculAr Profiling for Pediatric and Young Adult Cancer Treatment Stratification 2Gustave Roussy, Cancer Campus, Grand Paris · recruiting · Solid Tumor, Leukemia · principal investigator
- Ph1/Ph2NCT02813135 · European Proof-of-Concept Therapeutic Stratification Trial of Molecular Anomalies in Relapsed or Refractory TumorsGustave Roussy, Cancer Campus, Grand Paris · recruiting · Pediatric Cancer · study chair
- Ph2NCT00918320 · Studies of Temozolomide in Combination With Topotecan in Refractory and Relapsed Paediatric Solid TumoursGustave Roussy, Cancer Campus, Grand Paris · completed · Neuroblastoma, Brain Tumors, Solid Tumors · principal investigator
- Ph2NCT00407433 · Clinical Studies of Gemcitabine-OxaliplatinGustave Roussy, Cancer Campus, Grand Paris · completed · Medulloblastoma, Central Nervous System Tumors, Neuroblastoma · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-11 16:27 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-11 16:27 UTC. The ranking covers the 200 most relevant of 54 PubMed records, and a shared surname and initials can bring in a namesake. All 54 on PubMed
- Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1/2 clinical trials.Lancet Oncol · 2020856 citationsRCR 36.6
- 286 citationsRCR 7.3
- 279 citationsRCR 10.9
- Efficacy and Safety of Dabrafenib in Pediatric Patients with BRAF V600 Mutation-Positive Relapsed or Refractory Low-Grade Glioma: Results from a Phase I/IIa Study.Clin Cancer Res · 2019187 citationsRCR 7.2
- Preliminary efficacy of the anti-insulin-like growth factor type 1 receptor antibody figitumumab in patients with refractory Ewing sarcoma.J Clin Oncol · 2011177 citationsRCR 4.4
- Efficacy and Safety of Trametinib Monotherapy or in Combination With Dabrafenib in Pediatric BRAF V600-Mutant Low-Grade Glioma.J Clin Oncol · 2023176 citationsRCR 16.9
- 167 citationsRCR 5.0
- Efficacy and safety of larotrectinib in TRK fusion-positive primary central nervous system tumors.Neuro Oncol · 2022160 citationsRCR 10.6
- A Phase I Study of the CDK4/6 Inhibitor Ribociclib (LEE011) in Pediatric Patients with Malignant Rhabdoid Tumors, Neuroblastoma, and Other Solid Tumors.Clin Cancer Res · 2017152 citationsRCR 4.4
- Phase I study of oral sonidegib (LDE225) in pediatric brain and solid tumors and a phase II study in children and adults with relapsed medulloblastoma.Neuro Oncol · 2017149 citationsRCR 4.5